US Genomics and Lahey to Explore miRNA-based Urologic Cancer Biomarkers for Dx Development
US Genomics and Lahey to Explore miRNA-based Urologic Cancer Biomarkers for Dx Development
By Doug Macron
October 26, 2006
RNAi News
The deal, US Genomics? second involving miRNA-based diagnostics, gives the firm the right to commercialize products, which is something it doesn?t have under its first alliance, with Rosetta Genomics.
Paid subscription is required to view article.
